Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
Le Lézard4h
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") highlights the potential for its DPXtm non-systemic immune educating platform to address the inherent limitations of lipid ...
Ethereum Staking Meets Social Impact: Lido Impact Staking Officially Launches
Lido Impact Staking (LIS) officially launches on the 15th of January 2025, and introduces a new approach to sustainable ...
Pharm Exec21h
Johnson & Johnson Initiates New Drug Application for TAR-200 in BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer
The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...
Two ‘off-label’ chemo drugs successfully used together in Singapore to fight bladder cancer
They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.